|
|
| | 4-[4-Fluoro-1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-6-yl]-N-[5-[4-(1-methylethyl)-1-piperazinyl]-2-pyridinyl]-2-pyrimidinamine Basic information |
| | 4-[4-Fluoro-1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-6-yl]-N-[5-[4-(1-methylethyl)-1-piperazinyl]-2-pyridinyl]-2-pyrimidinamine Chemical Properties |
| Boiling point | 703.3±70.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | pka | 8.11±0.10(Predicted) |
| | 4-[4-Fluoro-1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-6-yl]-N-[5-[4-(1-methylethyl)-1-piperazinyl]-2-pyridinyl]-2-pyrimidinamine Usage And Synthesis |
| Uses | CDK2/4/6-IN-2 is a CKD2/4/6 inhibitor, with IC50 values less than 1 μM, 10 nM, 100 nM respectively[1]. | | IC 50 | CDK2; CDK4; CDK6 | | References | [1] Hu Zhilong, et al. Preparation of pyrimidine derivatives and related heterocycles as CDK inhibitors for the treatment of cancer. Patent. WO2020224568 A1 |
| | 4-[4-Fluoro-1-(1-methylethyl)-1H-imidazo[4,5-c]pyridin-6-yl]-N-[5-[4-(1-methylethyl)-1-piperazinyl]-2-pyridinyl]-2-pyrimidinamine Preparation Products And Raw materials |
|